Our findings suggest that (the lack of) ATG12-expression may serve as a useful predictive biomarker for clinical practice to identify cancer patients with a favorable prognosis and warrants future research in autophagy-potential of subclasses in other tumor types. Here, ATG12 is linked to cancer.